Barclays
OCGN icon

Barclays’s Ocugen OCGN Stock Holding History

Barclays’s Portfolio OCGN Stock Details OCGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$417K Buy
230,618
+73,118
+46% +$126K ﹤0.01% 3291
2025
Q4 		$213K Buy
+157,500
New +$224K ﹤0.01% 4276
2025
Q3 		– Sell
-60,400
Closed -$58.6K – 5658
2025
Q2 		$58.6K Sell
60,400
-253,888
-81% -$211K ﹤0.01% 4685
2025
Q1 		$222K Sell
314,288
-139,127
-31% -$96.2K ﹤0.01% 3988
2024
Q4 		$365K Sell
453,415
-127,672
-22% -$117K ﹤0.01% 4013
2024
Q3 		$577K Buy
581,087
+296,654
+104% +$407K ﹤0.01% 3688
2024
Q2 		$441K Buy
+284,433
New +$443K ﹤0.01% 3111
2023
Q2 		– Sell
-109,802
Closed -$93.7K – 4932
2023
Q1 		$93.7K Sell
109,802
-1,177,086
-91% -$1.28M ﹤0.01% 4220
2022
Q4 		$1.67M Buy
1,286,888
+84,646
+7% +$132K ﹤0.01% 2378
2022
Q3 		$2.14M Buy
1,202,242
+1,188,660
+8,752% +$2.96M ﹤0.01% 1704
2022
Q2 		$30K Buy
+13,582
New +$32.5K ﹤0.01% 4245
2018
Q2 		– Hold
0
– – – 7183
2018
Q1 		– Hold
0
– – – 7250

Other funds holding OCGN

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Barclays's OCGN Position: Q1 2026 in Review

Barclays increased its Ocugen (OCGN) stake by 46% in Q1 2026, buying an estimated $126K and bringing the position to 230,618 shares worth $417K. The position accounts for ﹤0.01% of the portfolio, ranked #3291.

Barclays first reported a position in OCGN in Q2 2022 and has held it in 11 quarters since. The position peaked at $2.14M in Q3 2022. 137 funds tracked by Wall St. Rank hold OCGN as of Q1 2026.

  • Barclays held 230,618 shares of Ocugen worth $417K as of Q1 2026.
  • Barclays bought 73,118 Ocugen shares in Q1 2026, an estimated $126K.
  • Ocugen made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3291 holding.
  • Barclays first reported a position in Ocugen in Q2 2022 and has held it in 11 quarters since.
  • Barclays's Ocugen position peaked at $2.14M in Q3 2022.
  • 137 funds tracked by Wall St. Rank held Ocugen as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.